Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
374.5 DKK | +1.33% |
|
+6.41% | -3.35% |
Jul. 02 | ChemoMetec A/S Announces Preliminary Revenue for the Fourth Quarter and Full Year of 2024 | CI |
May. 27 | Denmark's ChemoMetec Appoints New CFO | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an expected P/E ratio at 49.9 and 41.33 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.35% | 932M | D | ||
+75.69% | 12.57B | - | B- | |
-29.24% | 6.9B | C+ | ||
-8.77% | 5.69B | C- | ||
+5.81% | 5.04B | D+ | ||
-17.03% | 4.69B | B | ||
+17.07% | 4.18B | - | ||
-18.25% | 3.86B | B- | ||
-21.23% | 2.97B | C | ||
-0.99% | 1.99B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CHEMM Stock
- Ratings ChemoMetec A/S